Metabolic Dysfunction-associated Steatohepatitis
Conditions
Keywords
Metabolic Dysfunction-associated Steatohepatitis, ACT500, NM6606
Brief summary
This study is a multicenter, open-label, dose-escalation trial designed to evaluate the safety, tolerability, PK, and PD profiles of ACT500 in participants with metabolic dysfunction-associated steatotic liver disease (MASLD). The trial plans to enroll approximately 24 MASLD participants across four dose cohorts, each consisting of 6 participants who will receive oral ACT500 once daily.
Interventions
DRUGACT500 tablets
Once daily, orally
Sponsors
Xiamen Amoytop Biotech Co., Ltd.
Beijing Tsinghua Changgeng Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 69 Years
Healthy volunteers
No
Inclusion criteria
* The participant fully understands the purpose, nature, methods, and possible adverse reactions of the study, voluntarily participates in this study, and has signed the informed consent form. * Male or female participants aged between 18 and 69 years (inclusive of 18 and 69 years) at the time of signing the informed consent form. * Liver fat content (LFC) ≥10% as assessed by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) during the screening period. * Liver stiffness measurement (LSM) assessed by FibroScan during the screening period meets the criteria of 8 kPa ≤ LSM ≤ 15 kPa, OR a liver biopsy pathological result of F2/F3 fibrosis within 6 months prior to screening. * Serum alanine aminotransferase (ALT) \<5×ULN at screening. * Presence of at least one of the following metabolic risk factors: 1. BMI ≥ 24.0 kg/m\^2, or waist circumference ≥ 90 cm (males) and ≥ 85 cm (females); 2. Presence of prediabetes: fasting blood glucose ≥ 6.1 mmol/L, or glycated hemoglobin (HbA1c) ≥ 5.7%; 3. History of type 2 diabetes mellitus; 4. Fasting serum triglycerides (TG) ≥ 1.70 mmol/L but \< 5.6 mmol/L; 5. Fasting serum high-density lipoprotein cholesterol ≤ 1.0 mmol/L (males) or ≤ 1.3 mmol/L (females), or on stable-dose lipid-lowering medication (excluding statins); 6. Systolic blood pressure (SBP) ≥ 130 mmHg or diastolic blood pressure (DBP) ≥ 85 mmHg, while simultaneously meeting SBP ≤ 160 mmHg and DBP ≤ 100 mmHg, OR currently receiving a stable dose of antihypertensive medication and meeting SBP ≤ 160 mmHg and DBP ≤ 100 mmHg. * Both male and female participants must agree to use appropriate contraceptive methods, as follows: 1. For male participants: Agreement to use reliable contraceptive measures and refrain from sperm donation from signing the informed consent form until 1 months after the last dose. 2. For female participants: Female participants of non-childbearing potential; OR female participants of childbearing potential who are not pregnant or breastfeeding, have a negative serum pregnancy test at screening and within 1 day prior to the first dose, and agree to use reliable contraceptive measures and refrain from egg donation from signing the informed consent form until 1 months after the last dose.
Exclusion criteria
* \[1\] Combined with other liver diseases, including but not limited to hepatitis B, hepatitis C, drug-induced liver disease, alcoholic liver disease, autoimmune liver disease, suspected or confirmed hepatocellular carcinoma, etc. \[2\] Have a history of or currently have other malignancies, liver cirrhosis (including confirmed or suspected liver cirrhosis by imaging examination, or liver cirrhosis confirmed by liver biopsy), or have evidence of decompensated liver disease (such as ascites, esophageal and gastric variceal bleeding, or hepatic encephalopathy, etc.), or have a history of liver transplantation. \[3\] Have a history of or current symptoms of severe cardiovascular and cerebrovascular diseases, including but not limited to uncontrolled or severe arrhythmias (ventricular fibrillation, atrial fibrillation, etc.), myocardial infarction, coronary heart disease, etc. \[4\] Have a history of persistent, clinically significant respiratory, neurological, gastrointestinal, immunological, hematological, or psychiatric diseases, which, in the investigator's judgment, would pose additional risk to the participant. \[5\] Type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus (fasting plasma glucose \>9 mmol/L within 3 months prior to screening, or glycated hemoglobin \>9.5% at screening); or patients with diabetes receiving anti-hyperglycemic medications other than metformin and insulin. \[6\] Have an estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m² at screening or a history of severe renal impairment. \[7\] Have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia; or have hemoglobin \<105 g/L for female participants or \<115 g/L for male participants at screening; or any other condition known to interfere with hemoglobin measurement as judged by the investigator. \[8\] Any of the following laboratory abnormalities at screening: alkaline phosphatase (ALP) \>2×upper limit of normal (ULN); total serum bilirubin (TBIL) \>1.5×ULN (excluding participants with benign unconjugated hyperbilirubinemia deemed eligible for enrollment by the Investigator, with total bilirubin \<2×ULN and direct bilirubin \<ULN); international normalized ratio (INR) \>1.3. \[9\] Have had a body weight change (increase or decrease) of \>5% within 3 months prior to screening, or have undergone dieting, bariatric surgery, or used medications approved for weight loss indications. \[10\] Have a history of major trauma or surgery within 3 months prior to screening, or plan to undergo surgery during the study period. \[11\] Have a history of excessive alcohol consumption for 3 consecutive months or more within 1 year prior to screening, defined as a weekly ethanol intake of ≥210 g for males and ≥140 g for females; or have a history of drug abuse/dependence or a history of illicit drug inhalation/injection within 1 year prior to screening. \[12\] Have used medications that may have a therapeutic effect on MASLD/MASH (e.g., GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors, FGF21 analogs, resmetirom, etc.) or medications that may cause MASLD/MASH (e.g., amiodarone, methotrexate, tetracyclines, tamoxifen, estrogens at doses greater than hormone replacement therapy, anabolic steroids, valproic acid, other known hepatotoxic drugs, etc.) within 3 months prior to screening, or other medications that the investigator considers may affect the trial. \[13\] Have participated in another drug clinical trial within 3 months prior to screening. \[14\]Positive human immunodeficiency virus antibody (HIV-Ab) at screening; or positive treponema pallidum antibody together with positive rapid plasma reagin (RPR) test (RPR shall only be performed when treponema pallidum antibody is positive). \[15\] Have a known allergy to the excipients of ACT500 or to drugs with a similar chemical structure to ACT500, or have other drug allergies that, in the investigator's judgment, preclude participation in the study. \[16\] Have any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in this study, or are unable to participate in the trial due to the participant's own reasons after signing the informed consent form (ICF).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse Event#AE# | Day1-112 |
| Serious Adverse Event | Day1-112 |
| body temperature | Day 1,14,29,56,84,112 |
| Number of participants with treatment-related adverse events as assessed by NCI-CTCAE v6.0 | Day 1,14,29,56,84,112 |
| pulse | Day 1,14,29,56,84,112 |
| heart rate | Day 1,14,29,56,84,112 |
| blood pressure | Day 1,14,29,56,84,112 |
| Number of Participants with Abnormal Laboratory Parameters Findings | Day 1,14,29,56,84,112 |
| Number of participants with clinically significant change from baseline in physical examination | Day 1,14,29,56,84,112 |
| Heart Rate | Day 14,29,56,84,112, |
| PR Interval | Day 14,29,56,84,112, |
| QRS Interval | Day 14,29,56,84,112, |
| QT Interval | Day 14,29,56,84,112, |
| QTc Interval | Day 14,29,56,84,112, |
Secondary
| Measure | Time frame |
|---|---|
| Area Under Curve（0-t） | Day 1,2,14,28,29 |
| Area Under the Concentration-time curve from time zero to τ at steady state | Day 1,2,14,28,29 |
| Area Under Curve（0-∞） | Day 1,2,14,28,29 |
| Maximum Plasma Concentration | Day 1,2,14,28,29 |
| Time to Maximum (plasma) Concentration | Day 1,2,14,28,29 |
| Elimination Half-Life | Day 1,2,14,28,29 |
| CL/F | Day 1,2,14,28,29 |
| Apparent Volume of Distribution | Day 1,2,14,28,29 |
| Cmin,ss | Day 1,2,14,28,29 |
| Cav,ss | Day 1,2,14,28,29 |
| Rac_Cmax | Day 1,2,14,28,29 |
| Rac_AUC0-tau | Day 1,2,14,28,29 |
| DF | Day 1,2,14,28,29 |
| MRI-PDFF-determined liver fat content (LFC) | Day 29,112 |
| Fibroscan-measured liver stiffness measurement (LSM) | Day 29,112 |
| AST/PLT Ratio Index，APRI | Day 1,14,29,56,84,112 |
| absolute change from baseline in ELF | Day 1,14,29,56,84,112 |
| percent change from baseline in ELF | Day 1,14,29,56,84,112 |
| Total Cholesterol | Day 1,14,29,56,84,112 |
| Triglyceride | Day 1,14,29,56,84,112 |
| Low-Density Lipoprotein Cholesterol | Day 1,14,29,56,84,112 |
| High-Density Lipoprotein Cholesterol | Day 1,14,29,56,84,112 |
| apolipoprotein A1 | Day 1,14,29,56,84,112 |
| apolipoprotein B | Day 1,14,29,56,84,112 |
| absolute change from baseline in lipoprotein(a) | Day 1,14,29,56,84,112 |
| percent change from baseline in lipoprotein(a) | Day 1,14,29,56,84,112 |
| Alanine Aminotransferase | Day 1,14,29,56,84,112 |
| Aspartate Aminotransferase | Day 1,14,29,56,84,112 |
| Gamma-Glutamyl Transferase（GGT） | Day 1,14,29,56,84,112 |
| absolute change from baseline in GGT | Day 1,14,29,56,84,112 |
| percent change from baseline in GGT | Day 1,14,29,56,84,112 |
| body weight | Day 1,14,29,56,84,112 |
| body Mass Index | Day 1,14,29,56,84,112 |
| waist circumference | Day 1,14,29,56,84,112 |
| absolute change from baseline in hip circumference | Day 1,14,29,56,84,112 |
| High-sensitivity C-reactive protein | Day 1,2,14,28,29 |
| Tumor Necrosis Factor alpha | Day 1,2,14,28,29 |
| Cytokeratin 18 （M30） | Day 1,2,14,28,29 |
| N-terminal propeptide of type III collagen (Pro-C3) | Day 1,14,29 |
| absolute change from baseline in Pro-C3 | Day 1,1429 |
| percent change from baseline in Pro-C3 | Day 1,14,29 |
| Insulin-like Growth Factors-1 | Day 1,14,29 |
| Insulin-like Growth Factor Binding Protein 3 (IGFBP-3) | Day 1,29 |
| absolute change from baseline in IGFBP-3 | Day 1,29 |
| percent change from baseline in IGFBP-3 | Day 1,29 |
Countries
China
Contacts
CONTACTLai Wei
PRINCIPAL_INVESTIGATORLai Wei
Beijing Tsinghua Changgeng Hospital
Outcome results
None listed